Advanced Cancer
Conditions
Keywords
advanced cancer
Brief summary
This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With Advanced Solid Tumors.
Detailed description
This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With Advanced Solid Tumors. After the maximum tolerated dose (MTD) or the optimal biological dose is identified, an expansion cohort of \ 20 advanced renal cell carcinoma patients will be enrolled to further characterize the safety and tumor response by CT.
Interventions
DRUGCM082 Tablet
CM082 tablets taken orally once a day on 28-day cycles
Sponsors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
AnewPharma
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed diagnosis of advanced solid tumor malignancy that is not responsive to standard therapies or for which there is no effective therapy. * Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1. * Life expectancy of at least 12 weeks. * No immuno deficiency. * Adequate organ system function, defined as follows: * Absolute neutrophil count (ANC) ≥1.5 x 10\*\*9/L * Platelets ≥100 x 10\*\*9/L * Hemoglobin ≥10 g/dL * Total bilirubin ≤1.5 times the upper limit of normal (ULN) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5x the upper limit of normal (ULN) if no liver involvement or ≤2.5x the upper limit of normal with liver involvement. * Creatinine ≤ 1.5 x ULN. * At least 4 weeks or 5 half-life after receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization. * Willingness and ability to comply with trial and follow-up procedures. * Ability to understand the nature of this trial and give written informed consent.
Exclusion criteria
* Not recovered from prior anti-cancer therapy or surgery. * Have taken strong cytochrome P450 3A4 inhibitors or inducers in the last 2 weeks. * Concomitant use of drugs with a risk of causing prolonged corrected QT interval and/or Torsades de Pointes. * Patients with a history of intolerance to, or significant toxicity with, VEGFR tyrosine kinase inhibitor(s) (TKI). * Females who are pregnant or breastfeeding. * Those in reproductive ages who refuse to use contraception. * Those with concurrent condition(e.g. psychological, neuronal, cardiovascular, respiratory conditions or infections) that in the investigator's opinion would jeopardize compliance with the protocol. * Patients with known central nervous system (CNS) metastases. * Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of CM082 (X-82). * Patients with known GI disorders such as vomiting, diarrhea. * Patients who are hepatitis B virus positive. * Drug abuser.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose | 12 months | To determine the Maximum Tolerated Dose in Chinese patients with advanced solid tumors. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Preliminary biological activity | 24 months | clinical tumor response by computed tomography (CT) after treatment with CM082 tablets given as a single agent. |
| Area Under Curve | 2 months | — |
| Half-life time | 2 months | — |
| Cmax | 2 months | Peak concentration |
| Tmax | 2 months | Time to Cmax |
Countries
China
Outcome results
None listed